Background: The association between skeletal muscle and adipose tissue (body composition) and early response using positron emission tomography (PET) in pediatric Hodgkin lymphoma (HL) remains unstudied.
Methods: Patients enrolled on Children's Oncology Group studies AHOD0031 (intermediate-risk HL) and AHOD0831 (high-risk HL) with digital abdominal computed tomography (CT) scans at diagnosis and PET scans after 2 cycles (PET2) were included. Two consecutive slices at the third lumbar vertebra were identified and skeletal muscle index (SMI, in cm2/m2) and total adipose tissue index (TATI, in cm2/m2) were calculated using sliceOmatic (Magog, Canada) and height at diagnosis. SMI and TATI were divided into quintiles (Q1 [lowest] to Q5 [highest]). Body mass index (BMI) was calculated using height and weight at diagnosis. The association between baseline body composition (SMI, TATI, BMI) and positive PET2 was examined using logistic regression, adjusting for age at diagnosis, sex, race/ethnicity, stage, histology, bulk disease and 'B' symptoms.
Results: Among 1,033 included patients, PET2 was positive in 314 (30.4%). SMI was not associated with positive PET2. Extremes of TATI were associated with positive PET2, when compared with the middle TATI quintile (reference: Q3; odds ratio [ORQ1]=1.63, 95% confidence interval [CI]=1.03-2.60, P=0.04; ORQ2=1.82, 95%CI=1.17-2.82, P=0.008; ORQ5=1.94, 95%CI=1.23-3.05, P=0.005). The association between BMI in obesity range and positive PET2 trended towards significance (OR=1.42, 95%CI=0.98-2.04, P=0.06; ref=normal weight).
Conclusions: Extremes of adipose tissue at diagnosis influences early response among pediatric HL.
Impact: Validation of results from this study could inform studies investigating body composition-based chemotherapy dosing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1055-9965.EPI-24-1231 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Body Composition at Diagnosis and Early Response in Pediatric Hodgkin Lymphoma.
Cancer Epidemiol Biomarkers Prev
January 2025
University of Alabama at Birmingham, Birmingham, AL, United States.
Background: The association between skeletal muscle and adipose tissue (body composition) and early response using positron emission tomography (PET) in pediatric Hodgkin lymphoma (HL) remains unstudied.
Methods: Patients enrolled on Children's Oncology Group studies AHOD0031 (intermediate-risk HL) and AHOD0831 (high-risk HL) with digital abdominal computed tomography (CT) scans at diagnosis and PET scans after 2 cycles (PET2) were included. Two consecutive slices at the third lumbar vertebra were identified and skeletal muscle index (SMI, in cm2/m2) and total adipose tissue index (TATI, in cm2/m2) were calculated using sliceOmatic (Magog, Canada) and height at diagnosis.
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD.
Leuk Lymphoma
January 2025
Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.
Brentuximab vedotin (BV) plus doxorubicin, vinblastine and dacarbazine (AVD) demonstrated to improve survival compared to ABVD as frontline treatment of advanced stage Hodgkin Lymphoma (HL). We retrospectively collected data of 99 stage IV HL patients treated off-protocol with BV-AVD to evaluate the predictive role of interim-PET. Median age was 36 years (range: 18-82); 83.
View Article and Find Full Text PDFClinical Factors That Influence Repeat Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
J Nucl Med
October 2024
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
This analysis aimed to identify clinical factors associated with positivity on repeat Ga-PSMA-11 PET/CT after a negative scan in patients with recurrent prostate cancer (PCa) under observation. This single-center, retrospective analysis included patients who underwent at least 2 Ga-PSMA-11 PET/CT scans (PET1 and PET2) at UCLA between October 2016 and June 2021 for recurrent PCa with negative PET1 and no PCa-related treatments between the 2 scans. Using Prostate Cancer Molecular Imaging Standardized Evaluation criteria to define negative and positive scans, the final cohort was divided into PET2-negative (PET2-Neg) and PET2-positive (PET2-Pos).
View Article and Find Full Text PDFInterim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305).
Cancer Sci
October 2024
Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Article Synopsis
- A study called JCOG1305 tested a new way to treat young people with advanced classic Hodgkin lymphoma (cHL) using a special PET scan after two treatment cycles.
- Patients aged 16-60 received specific chemotherapy and then their PET scans determined if they continued the same treatment or switched to a stronger one.
- The results showed that most patients had a good chance of staying cancer-free for at least two years, making the PET-guided treatment a promising option for younger patients with this type of cancer.
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects.
Front Oncol
April 2024
Department of Hematology/Oncology, Brown University, Providence, RI, United States.
Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory (R/R) regimens. In first-line therapy, the synergy between ICIs and chemotherapy may surpass the previous standards of ABVD and BV-AVD established by landmark trials including RATHL and ECHELON-1. In R/R disease, the combination of ICIs with chemotherapy has begun to challenge the paradigm of chemotherapy as a bridge to consolidative autologous stem cell transplantation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!